Clerk of the House of Representatives Secretary of the Senate Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Office of Public Records 232 Hart Building Washington, DC 20510

SECRETARY OF THE SE PUBLIC RECORDS

03 JAN 27 AH 10:

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name			
Marc B. Samuels			
2. Address Check if different than previously reported			
823 Congress, Suite 900			
3. Principal Place of Business (if different from line 2)			
City: Austin State/	Zip (or Country) TX 78701		
4. Contact Name Telephone	E-mail (optional) 5. Senate ID#		
Marc B. Samuels (512) 480-896	(512) 480-8962		
7. Client Name Self	6. House ID #		
Pharmaceutical Research & Manufacturers of America			
10. Check if this is a Termination Report □ ⇒ Termination INCOME OR EXPENSES - Complete Eithe	•		
12. Lobbying Firms	13. Organizations		
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reperiod were:		
Less than \$10,000 🗀	Less than \$10,000 🚨		
\$10,000 or more 🗹 🗢 \$\$60,000.00	\$10,000 or more		
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicat accounting method. See instructions for description o		
	Method A. Reporting amounts using LDA definit		
	Method B. Reporting amounts under section 603 Internal Revenue Code		
	Method C. Reporting amounts under section 162 Internal Revenue Code		
Signature vs &			
Printed Name and Title Marc	B. Samuels		

LD-2 (REV. 6/98)

Registrant Name	Març B. Samuels	Client Name_	Pharmaceutical Research & Manufacturers of Ar
engaged in lobbying		ig the reporting j	o reflect the general issue areas in which the period. Using a separate page for each cod
15. General issue ar	ea code MED (one	per page)	
16. Specific lobbyin Legislation and re and drugs; medica		ood and Drug Adm iologics and drugs	inistration; FDA approval and regulation of biologi
17. House(s) of Cor	ngress and Federal agencies	contacted	☐ Check if None
US Department Office of Manag	care and Medicaid Services of Health and Human Services gement and Budget es of the President dministration		
18. Name of each in	ndividual who acted as a lob	byist in this issu 	
Marc B. Samuels	Name		Covered Official Position (if applicable)
		•	
		.444.949.4	
19. Interest of each fo	oreign entity in the specific issu	l les listed on line 1	6 above
	20:04		
Signature			Date 01/14/03
Printed Name and Tit	_{le} Marc B. Samuels		

Form LD-2 (Rev.6/98)

Page _

Registrant Name	Març B. Samuels	Client Name_	Pharmaceutical Research & Manufacturers of Ar
engaged in lobbying		g the reporting	o reflect the general issue areas in which the period. Using a separate page for each cod
15. General issue are	ea code MMM (one	per page)	
16. Specific lobbying	g issues		
	gulatory issues related to the Fo id and medicare coverage of b		ninistration; FDA approval and regulation of biologi
17. House(s) of Con	gress and Federal agencies	contacted	☐ Check if None
US Department Office of Manag	care and Medicaid Services of Health and Human Servi ement and Budget es of the President	ces	
18. Name of each in	dividual who acted as a lob	byist in this issu	ue area
	Name		Covered Official Position (if applicable)
Marc B. Samuels			
\			

		••••	
19. Interest of each fo	oreign entity in the specific issu	ues listed on line	16 above
Signature	me	<u> </u>	Date 01/14/03
Printed Name and Tit	le Marc B. Samuels		

Form LD-2 (Rev.6/98)

Page _